Professor Michael Dickinson

Professor Michael Dickinson is Lead of the Aggressive Lymphoma stream and provides care for patients with all forms of lymphoma, myeloma, myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). He convenes the Lymphoma Multidisciplinary Meeting (MDM), serves as Deputy Clinical Lead of the CAR-T Centre of Excellence, and is Chair of the Lymphoma Working Party of the Australasian Leukaemia and Lymphoma Group, as well as Chair of the Clinical Research Committee at Peter MacCallum Cancer Centre.

Professor Dickinson has a strong focus on drug development and early-phase clinical trials. As Principal Investigator, he has treated the first patient globally in multiple first-in-human studies and has helped take several novel therapies through to registration. He treated the first patients worldwide in trials of glofitamab, a bispecific antibody for lymphoma, as well as epigenetic agents such as BET inhibitors, NKX019 (CAR-NK cells), YTB323 (rapcabtagene autoleucel), and ELARA, a CAR-T registration trial for follicular lymphoma. His team were the first to use YESCARTA and KYMRIAH both in clinical trials and commercially in Australia, and were the highest ex-US recruiters to pivotal CAR-T trials in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.

He was the lead investigator in the registration trial of the first-in-class agent glofitamab and has authored more than 100 peer-reviewed publications, including in the New England Journal of Medicine, Nature Medicine, the Journal of Clinical Oncology and Blood. Professor Dickinson is committed to mentoring research fellows and PhD students, supporting their academic and professional development.